Paraza Pharma Inc. is pleased to announce a recent joint publication that was coauthored with Repare Therapeutics.
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ
Paraza Pharma Inc. is pleased to announce a recent joint publication that was coauthored with Repare Therapeutics.
Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ
Canada: +1 514-395-4501
info@parazapharma.com
© Paraza Pharma, Inc. All rights reserved.
Privacy policy